Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab PK Comparability Study (APFS vs AI)
NCT02968914Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2017
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of benralizumab in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Concentration-time Curve From Zero to Infinity at Day 57, Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration at Day 57 and 1 more. Started Jan 2017; status: completed.
02
Drugs
benralizumab
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02968914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968914.